⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 29, 2024Journal of NephrologyOpen Access

Eculizumab for adult patients with atypical haemolytic-uraemic syndrome: full dataset analysis of Japanese post-marketing surveillance

Shoichi Maruyama Yoichiro Ikeda Shinya Kaname Noritoshi Kato Masanori Matsumoto Yumiko Ishikawa Akihiko Shimono Yoshitaka Miyakawa Masaomi Nangaku Yugo Shibagaki Hirokazu Okada

View Full Paper

Ask AI

Bookmark

Share

Abstract

Eculizumab has been approved for atypical haemolytic-uraemic syndrome (aHUS) in Japan since 2013. Post-marketing surveillance enrolled patients with aHUS who received ≥ 1 dose of eculizumab to assess eculizumab safety and effectiveness.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Maruyama et al. (2024) studied this question.

synapsesocial.com/papers/68e67e1cb6db643587607845 https://doi.org/10.1007/s40620-024-01921-y

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Long-Term Therapy with Eculizumab Biosimilar in Patients with Atypical Haemolytic Uraemic Syndrome: Outcomes of a Prospective Observational StudyObservational Study · 2026
2Application of eculizumab, a terminal complement inhibitor, in the management of atypical hemolytic uremic syndrome in a 14-month-old Chinese pediatric patient: a case report2024 · 3 citations
3#550 Characteristics of patients with aHUS who discontinued dialysis after eculizumab treatment: sub-analysis of post-marketing surveillance in Japan2024
4Eculizumab for Atypical Hemolytic Uremic Syndrome: Guidance for Developing Countries2025 · 3 citations
5Biosimilar eculizumab for the treatment of pregnancy associated atypical hemolytic uremic syndrome: a retrospective comparative study2024